Alcoholic Liver Disease Clinical Trial
Official title:
A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease
It is proposed to test metadoxine (MTDX) that it is hypothesized to be significantly beneficial for the treatment of alcoholism and ALD. Metadoxine is currently approved in Europe for acute and chronic alcohol intoxication but has never been tested in the US. Furthermore, MTDX is used in Europe to treat ALD. Preliminary evidence shows that MTDX reduces alcohol consumption in AD individuals. If the role of MTDX in reducing alcohol consumption and improve liver function is confirmed by a rigorous study design, then MTDX might represent a truly innovative pharmacotherapy for AD, given the potential to be used for AD individuals with ALD. However until this proposal, MTDX has never been investigated as a treatment for AD able to reduce both alcohol consumption and improve alcohol-related liver damage via a double-blind placebo-controlled study. This project therefore proposes to conduct a 12-week (followed by a 3-month follow-up), double-blind, placebo-controlled, between-subject randomized clinical trial with MTDX (500mg t.i.d.) in AD individuals.
Treatments for ALD have limited success when drinking continues. Cessation of alcohol consumption or a significant reduction in alcohol intake improves histology and survival of patients with any stage of ALD. While alcohol abstinence may not be sufficient to provide a total recovery of ALD, patients with uncomplicated ALD have a 5-year survival of almost 90% if they stop drinking. Consequently, abstinence is the most important therapeutic intervention for patients with ALD. When combined with psychosocial treatments, currently approved medications can improve outcomes for some AD individuals; however, these treatments are unsuccessful for many others. One of the limiting factors that must be taken into consideration when using currently approved medications such as disulfiram or naltrexone is liver function. Given their hepatic metabolism, disulfiram or naltrexone both increase the risk of hepatotoxicity in AD individuals. Therefore, a pharmacotherapy that is effective for AD, that is safe for the liver and able to recover alcohol-related liver damage thereby improving liver function, would be an ideal medication. However as of now, no drug has been found to provide all of these benefits to AD individuals. It is proposed therefore to test metadoxine (MTDX) that it is hypothesized is significantly beneficial for the treatment of alcoholism and ALD. Metadoxine is currently approved in Europe for acute and chronic alcohol intoxication but has never been tested in the US. Furthermore, MTDX is used in Europe to treat ALD. Preliminary evidence shows that MTDX reduces alcohol consumption in AD individuals. If the role of MTDX in reducing alcohol consumption and improve liver function is confirmed by a rigorous study design, then MTDX might represent a truly innovative pharmacotherapy for AD, given the potential to be used for AD individuals with ALD. However until this proposal, MTDX has never been investigated as a treatment for AD able to reduce both alcohol consumption and improve alcohol-related liver damage via a double-blind placebo-controlled study. This project therefore proposes to conduct a 12-week (followed by a 3-month follow-up), double-blind, placebo-controlled, between-subject randomized clinical trial with MTDX (500mg t.i.d.) in AD individuals. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00708617 -
FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease
|
N/A | |
| Completed |
NCT00990639 -
Effect of Candesartan in Alcoholic Liver Fibrosis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04106518 -
Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
|
||
| Recruiting |
NCT04666402 -
Integrated Diagnostics for Early Diagnosis of Liver Disease
|
||
| Recruiting |
NCT02331745 -
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
|
Phase 4 | |
| Completed |
NCT01501162 -
Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
|
Phase 4 | |
| Recruiting |
NCT05895890 -
French National MICMAF Cohort
|
||
| Completed |
NCT04557774 -
Cognitive Function of Alcoholic Compensated Liver Cirrhosis
|
||
| Recruiting |
NCT03267069 -
Evaluating Alcohol Use in Alcoholic Liver Disease
|
||
| Recruiting |
NCT03295812 -
Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)
|
N/A | |
| Recruiting |
NCT05855031 -
The Liver Care Trial
|
N/A | |
| Not yet recruiting |
NCT03503708 -
Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
|
N/A | |
| Completed |
NCT02796469 -
Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis
|
N/A | |
| Completed |
NCT02140294 -
Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease
|
N/A | |
| Recruiting |
NCT03209791 -
Ethanol Induces Skeletal Muscle Autophagy
|
||
| Recruiting |
NCT04400604 -
Study of Alcohol-related Liver Disease in Europe
|
||
| Recruiting |
NCT04736966 -
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
|
Phase 1 | |
| Completed |
NCT03402256 -
Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients
|
N/A | |
| Completed |
NCT01711125 -
Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease
|
Phase 3 | |
| Active, not recruiting |
NCT03863730 -
Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota
|
N/A |